Long-term natalizumab treatment is associated with a reduction in lesional white matter levels of myo-inostiol, a biomarker of gliotic activity

Research output: Contribution to conferencePosterAcademic

Original languageEnglish
Publication statusPublished - 1 Jul 2019
Event5th Congress of the European Academy of Neurology - Oslo, Norway
Duration: 29 Jun 20192 Jul 2019

Conference

Conference5th Congress of the European Academy of Neurology
Abbreviated titleEAN
CountryNorway
CityOslo
Period29/06/201902/07/2019

Cite this

@conference{aa258c3e860649f18c05929262ceded0,
title = "Long-term natalizumab treatment is associated with a reduction in lesional white matter levels of myo-inostiol, a biomarker of gliotic activity",
author = "MM Schoonheim and LE Jonkman and AJC Eijlers and KA Meijer and J Killestein and JJG Geurts",
year = "2019",
month = "7",
day = "1",
language = "English",
note = "5th Congress of the European Academy of Neurology, EAN ; Conference date: 29-06-2019 Through 02-07-2019",

}

Long-term natalizumab treatment is associated with a reduction in lesional white matter levels of myo-inostiol, a biomarker of gliotic activity. / Schoonheim, MM; Jonkman, LE; Eijlers, AJC; Meijer, KA; Killestein, J; Geurts, JJG.

2019. Poster session presented at 5th Congress of the European Academy of Neurology, Oslo, Norway.

Research output: Contribution to conferencePosterAcademic

TY - CONF

T1 - Long-term natalizumab treatment is associated with a reduction in lesional white matter levels of myo-inostiol, a biomarker of gliotic activity

AU - Schoonheim, MM

AU - Jonkman, LE

AU - Eijlers, AJC

AU - Meijer, KA

AU - Killestein, J

AU - Geurts, JJG

PY - 2019/7/1

Y1 - 2019/7/1

M3 - Poster

ER -